Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a pioneering clinical-stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products. These novel drugs aim to treat significant diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is at the forefront of creating the first therapeutics that induce a shift towards health by enhancing the microbiome's biology.
The company operates primarily in the United States, leveraging its microbiome therapeutics platform to develop Ecobiotic™ microbiome therapeutics. These therapies are designed to restore health by repairing the function of a dysbiotic microbiome, particularly in the colon. Seres' lead product, SER-109, is developed to prevent the recurrence of Clostridium difficile infection (CDI), a severe infection of the colon. Additional product candidates include SER-262, SER-287, and SER-401.
Recently, Seres announced the sale of its VOWST assets to Nestlé Health Science under a non-binding memorandum of understanding. This transaction will provide Seres with capital infusions, including an upfront payment, and is expected to be completed in the next 90 days, subject to shareholder approval and other conditions. VOWST, the first FDA-approved oral microbiome therapy, prevents the recurrence of CDI in adults following antibacterial treatment for recurrent CDI.
Seres plans to use the capital from this transaction to retire its existing debt and strengthen its financial position. The company is also advancing SER-155, evaluated in a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation. SER-155 has the potential to reduce gastrointestinal and related bloodstream infections, as well as acute graft-versus-host disease.
Seres Therapeutics continues to innovate in microbiome therapeutics, aiming to benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The company's approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).
Seres Therapeutics, Inc. (Nasdaq: MCRB) has partnered with Nestlé Health Science to co-commercialize SER-109, a microbiome therapy targeting recurrent Clostridioides difficile infection, in the U.S. and Canada. Seres will receive $175 million upfront and $125 million upon FDA approval, plus up to $225 million in sales milestones. Upon commercialization, Seres will earn 50% of profits. SER-109 aims to be the first FDA-approved microbiome therapy, with promising clinical results indicating a 27% absolute reduction in CDI recurrence. A Joint Steering Committee will oversee collaboration activities.
Seres Therapeutics (Nasdaq: MCRB) will host a virtual investor event on June 21, 2021, from 8:30 a.m. to 10:00 a.m. ET, to discuss its investigational therapies SER-287 and SER-301 for ulcerative colitis (UC). Management and Dr. Stephen Hanauer will highlight the UC patient burden and the need for new treatments. SER-287 is in a Phase 2b trial for active mild-to-moderate UC, with data expected mid-2021. SER-301 is under evaluation in a Phase 1b study. Interested participants can join via the company's website or conference call.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a microbiome therapeutics leader, announced that its Chief Commercial and Strategy Officer, Terri Young, Ph.D., will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 1:00 p.m. ET. The presentation will be accessible via an audio webcast on Seres’ website and will be archived for 21 days post-event. Seres is developing a novel class of multifunctional bacterial therapies, with its SER-109 program targeting recurrent C. difficile infection and SER-287 aimed at pediatric ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced that the FDA has approved the IND application for SER-155, an investigational microbiome therapeutic aimed at reducing gastrointestinal infections in immunocompromised patients. The Phase 1b study will include around 70 patients to assess the safety and efficacy of SER-155 in preventing infections and graft-versus-host disease (GvHD) post-allogeneic hematopoietic stem cell transplantation (HSCT). SER-155 has potential to significantly impact treatment outcomes for patients facing serious antibiotic-resistant infections.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced participation in two upcoming investor conferences: the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:30 p.m. ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 11:20 a.m. ET. An audio webcast of both presentations will be available on Seres’ website for 21 days post-event. Seres specializes in microbiome therapeutics, with notable programs like SER-109 for recurrent C. difficile infections, awarded Breakthrough Therapy designation by the FDA.
Seres Therapeutics (Nasdaq: MCRB) announced compelling results from the Phase 3 ECOSPOR III study of SER-109, a microbiome therapy for recurrent C. difficile infection (rCDI). The final 24-week data revealed a recurrence rate of 21.3% for SER-109 compared to 47.3% for placebo, showcasing a 54% relative risk reduction (p < 0.001). The safety profile was comparable to placebo, reinforcing SER-109's potential as a first-in-class treatment. Clinical data will be presented during Digestive Disease Week 2021, alongside advancements in SER-287 and SER-301 for ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has appointed David Arkowitz as the new Executive Vice President and Chief Financial Officer, effective June 1, 2021. Arkowitz brings over 30 years of experience in finance and operations from notable companies in the biotech sector, enhancing Seres' leadership team amid its pivotal SER-109 program approaching BLA submission. The company is focused on developing microbiome therapeutics, with SER-109 showing promise for recurrent C. difficile infection. The firm has received Breakthrough Therapy and Orphan Drug designations from the FDA.
Seres Therapeutics (MCRB) announced the presentation of early-stage clinical research at the ASCO Annual Meeting from June 4-8, 2021. The oral presentation will focus on microbiome diversity in hematopoietic stem cell transplantation, while a poster presentation will assess microbiome composition in relation to cancer treatment responses. The findings aim to enhance the understanding of microbiome therapeutics and their role in improving cancer treatment outcomes and reducing antibiotic-resistant infections.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on May 18 at 4:15 p.m. ET. A live audio webcast can be accessed on their website under the 'Investors and News' section, with a replay available for 21 days post-event. Seres Therapeutics is pioneering microbiome therapeutics with its SER-109 program, showing promising results for recurrent C. difficile infection, and has received Breakthrough Therapy and Orphan Drug designations from the FDA. The company is also advancing programs for ulcerative colitis and gastrointestinal infections.
Seres Therapeutics (Nasdaq: MCRB) announced its participation in the virtual Digestive Disease Week (DDW) from May 21-23, 2021, showcasing its microbiome drug development. The company will present findings on investigational therapies SER-109, SER-287, and SER-301 aimed at treating recurrent Clostridioides difficile infection and ulcerative colitis. CDI poses a significant healthcare burden in the U.S., costing about $6.3 billion annually. Seres aims to address the urgent need for effective treatments, with SER-109 receiving FDA Breakthrough Therapy and Orphan Drug designations.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
What does Seres Therapeutics, Inc. do?
What is SER-109?
What recent transaction did Seres Therapeutics announce?
What is VOWST?
What is the financial condition of Seres Therapeutics?
Who founded Seres Therapeutics?
What other products are in Seres Therapeutics' pipeline?
What partnerships does Seres Therapeutics have?
What is the company's approach to treating diseases?
Where can I find more information about Seres Therapeutics?
